The company said that EPS for next year is anticipated to be between $3.50 and $3.60. On an adjusted basis, EPS is expected in the range of $4.25 to $4.35.
The firm beat the consensus Wall Street estimates on the top and bottom lines as the diagnostics segment saw revenues grow 20 percent year over year.
A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.
Overall growth was driven by the company's diagnostics segment, which rose 11 percent, while life sciences improved 6 percent
The deal gives Beckman Coulter non-exclusive distribution rights in the US and Canada to the NGS library preparation kits for cell-free DNA in plasma.
The Beckman Coulter unit provides genomic sequencing solutions to healthcare businesses, governments, and academia around the world.
IncellDx's investigational molecular assay used to quantify HPV E6/E7 mRNA in single cells has been optimized to run on Beckman Coulter's CytoFlex flow cytometry system.
Following a beta evaluation of the system, a virology lab in Sheffield, UK, ran a workflow assessment and found improvements with the system.
The DxN Veris was recently launched as a CE-marked product with a menu of viral load tests, and will launch in a few years in the US with STD and HAI assays.
The assays add to the test menu of Beckman Coulter's DxN Veris molecular diagnostics system.
Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.
University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.
The Wall Street Journal examines billing codes used by uBiome.
In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.